Search
Imlunestrant
go.drugbank.com/drugs/DB19043ApprovedInvestigational[L54046] Imlunestrant works by antagonizing ER transcriptional activity and, by forming an unstable drug-receptor complex, promotes ER degradation via the ubiquitin-proteasome pathway.
Macimorelin
go.drugbank.com/drugs/DB13074ApprovedMacimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution.
Calfactant
go.drugbank.com/drugs/DB06415ApprovedInvestigationalCalfactant is a sterile, non-pyrogenic lung surfactant intended for intratracheal instillation. It is an off-white suspension of an extract of natural surfactant from calf lungs suspended in 0.9% saline. Each milliliter of calfactant con...
Trabectedin
go.drugbank.com/drugs/DB05109ApprovedInvestigationalTrabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. I...
Avanafil
go.drugbank.com/drugs/DB06237ApprovedIn comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively
Dithiazanine
go.drugbank.com/drugs/DB11516ApprovedVet approvedWithdrawnDithiazanine iodide has been withdrawn from the market in countries such as France in Italy, but it may remain available in others.[A254427,L44032]
Secobarbital
go.drugbank.com/drugs/DB00418ApprovedVet approvedSecobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties.
Aluminum oxide
go.drugbank.com/drugs/DB11342ApprovedWithdrawnIt is considered an indirect additive used in food contact substances by the FDA.
Polatuzumab vedotin
go.drugbank.com/drugs/DB12240ApprovedInvestigational[L6658] Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 [A254936] and was approved by Health Canada on July 9, 2020.[L44141]
Mycophenolic acid
go.drugbank.com/drugs/DB01024ApprovedInvestigational[A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic acid release until